Refractory epilepsy in pediatrics: Diagnosis and treatment;Epilepsias refractarias en pediatría. Diagnóstico y tratamiento

Acta Pediatrica Espanola

Volumn 65, Issue 4, 2007, Pages 157-164

  Lopez Pison J ^a   Garcia Oguiza A ^a   Saenz De C A ^a   Caceres A ^a   Eiras, J ^a   Bertol, V ^a   Pena Segura J L ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Adrenocorticotropic hormone (ACTH); Antiepileptic drugs; Children; Corticosteroids; Drug resistance; Epilepsy surgery; Immunoglobulins; Ketogenic diet; Refractory epilepsy; Vagus nerve stimulation

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CORTICOSTEROID; CORTICOTROPIN; ETIRACETAM; GABAPENTIN; IMMUNOGLOBULIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

AGE DISTRIBUTION; BRAIN DEVELOPMENT; DISEASE DURATION; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; EPILEPSY; FOOD AND DRUG ADMINISTRATION; GAMMA KNIFE RADIOSURGERY; HUMAN; KETOGENIC DIET; NERVE CELL PLASTICITY; NEUROIMAGING; PALLIATIVE THERAPY; POSITRON EMISSION TOMOGRAPHY; PSYCHOMOTOR DEVELOPMENT; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURGICAL TECHNIQUE; SYMPTOM; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION;

EID: 34248634017     PISSN: 00016640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Devinsky O. Patients with refractory seizures. N Engl J Med. 1999; 340: 1.565-1.570.
2. Arzimanoglou A. Treatment options in pediatric epilepsy syndromes. Epileptic Disord. 2002; 4: 217-225.
3. Raffo E. Critères de pharmaco-résistance d'une épilepsie: les critères du neuropédiatre. Rev Neurol (Paris). 2004; 160 Supl 5: 48-52.
4. Genton P, McMenamin J. Aggravation of seizures by antiepileptic drugs: what to do in clinical practice. Epilepsia. 1998; 39 Supl 3: 26-29.
5. Arroyo S, Brodie MJ, Avanzini G, Baumgartner C, Chiron C, Dulac O, et al. Is refractory epilepsy preventable? Epilepsia. 2002; 43: 437-444.
6. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability ot the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the AES. Neurology. 2004; 62: 1.261-1.273.
7. Genton P. When antiepileptic drugs aggravate epilepsy? Brain Dev. 2000; 22: 75-80.
8. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia. 1998; 39 Supl 3: 2-10.
9. Catania S, Cross H, De Sousa C, Boyd S. Paradoxic reaction to lamotrigine in a child with benign focal epilepsy of childhood with centrotemporal spikes. Epilepsia. 1999; 40: 1.657-1.660.
10. Hamnao SI, Mochizucki M, Morikawa T. Phenobarbital-induced atypical absence seizure in benign childhood epilepsy with centrotemporal spikes. Seizure. 2002; 11: 201-204.
11. Shields WD, Saslow E. Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology. 1983; 33: 1.487-1.489.
12. Yang MT, Lee WT, Chu LW, Shen YZ. Anti-epileptic drugs-induced de novo absence seizures. Brain Dev. 2003; 25: 51-56.
13. Lerman-Sagie T, Watemberg N, Kramer U, Lerman P. Absence seizures aggravated by valproic acid. Epilepsia. 2001; 42: 941-943.
14. Prats JM, Garaizar C, García-Nieto ML, Madoz P. Antiepileptic drugs and atypical evolution of idiopathic partial epilepsy. Pediatr Neurol. 1998; 18: 402-406.
15. Fejerman N, Carballo R, Tenembaum SN. Evoluciones atípicas de la epilepsia parcial benigna de la infancia con espigas centrotemporales. Rev Neurol. 2000; 31: 389-396.
16. Fejerman N, Carballo R, Tenembaum SN. Atypical evolution or benign localization-related epilepsies in children: are they predictable? Epilepsia. 2000; 41: 380-390.
17. Ohtsuka Y, Sato M, Oka E. Nonconvulsive status epilepticus in childhood localization-related epilepsy. Epilepsia. 1999; 40: 1.003-1.010.
18. Mitchell WG. Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment. Epilepsia. 1996; 37 Supl 1: 74-80.
19. Callahan DJ, Noetzel MJ. Prolonged absence status epilepticus associated with carbamazepine therapy, increased intracranial pressure, and transient MRI abnormalities. Neurology. 1992; 42: 2.198-2.201.
20. Ettinger AB, Bernal OG, Andriola MR, Baghi S, Flores P, Just C, et al. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy. Epilepsia 1999; 40: 1.159-1.162.
21. Piccinelli P, Borgatti R, Perucca E, Tofani A, Donati G, Balottin U. Frontal nonconvulsive status epilepticus associated with high-dose tiagabine therapy in a child with familial bilateral perisylvian polymicrogyria. Epilepsia. 2000; 41: 1.485-1.488.
22. Adelson PD. Temporal lobectomy in children with intractable seizures. Pediatr Neurosurg. 2001; 34: 268-277.
23. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B. Early development of intractable epilepsy in children: a prospective study. Neurology. 2001; 56: 1.445-1.452.
24. Crumrine C. Antiepileptic drug selection in pediatric epilepsy. J Child Neurol. 2002; 17 Supl 2: 2-8.
25. Farrell K. Classifying epileptic syndromes: problems and a neurobiological solution. Neurology. 1993; 43 Supl 5: 8-11.
26. Berg AT, Shinnar S. The contributions of epidemiology of the understanding of childhood seizures and epilepsy. J Child Neurol. 1994; 9 Supl 2: 19-26.
27. Aicardi J. Syndromic classification in the management of childhood epilepsy. J Child Neurol. 1994; 9 Supl 2: 14-18.
28. Musicco M, Beghi E, Solari A, Viani F, for the First Seizure Trial Group (FIRST Group). Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. Neurology. 1997; 49: 991-998.
29. Shinnar S, Berg AT. Does antiepileptic drug therapy prevent the development of chronic epilepsy? Epilepsia. 1996; 37: 701-708.
30. Sillanpää M. Remission of seizures and predictors of intractability in long-term follow-up. Epilepsia. 1993; 34: 930-936.
31. Berg AT, Levy SR, Novotny EJ, Shinnar S. Predictors of intractable epilepsy in childhood: a case-control study. Epilepsy. 1996; 37: 24-30.
32. Sim SK, Wang KC, Hwang YS, Kim KJ, Kim IO, Lee DS. Pediatric intractable epilepsy: the role of presurgical evaluation and seizure outcome. Child's Nerv Syst. 2000; 16: 278-286.
33. Wyllie E. Surgical treatment of epilepsy in children. Pediatr Neurol. 1998; 19: 179-188.
34. Cuéllar R, Molinero M. Tratamiento de los niños con epilepsia de difícil control. Rev Neurol. 2003; 37: 371-375.
35. Sánchez-Álvarez JC, Serrano-Castro PJ, Cañadillas- Hidalgo F. Epilepsia refractaria del adulto. Rev Neurol. 2002; 35: 931-953.
36. Camfield PR, Camfield CS. Vagal nerve stimulation for treatment of children with epilepsy. J Pediatr. 1999; 134: 532-533.
37. Zupang ML. Neuroimaging in the evaluation of children and adolescents with intractable epilepsy (II). Neuroimaging and pediatric epilepsy surgery. Pediatr Neurol. 1997; 17: 111-121.
38. Goyal M, Bangert BA, Lewin JS, Cohen ML, Robinson S. High-resolution MRI enhances identification of lesions amenable to surgical therapy in children with intractable epilpesy. Epilepsia. 2004; 45: 954-959.
39. Sinclair DB, Wheatley M, Aronyk K, Hao C, Snyder T, Colmers W, et al. Pathology and neuroimaging in pediatric temporal lobectomy for intractable epilepsy. Pediatr Neurosurg. 2001; 35: 239-246.
40. Leiphart JW, Peacock WJ, Mathern GW. Lobar and multilobar resections for medically intractable pediatric epilepsy. Pediatr Neurosurg. 2001; 34: 311-318.
41. Sinclair DB, Aronyk K, Snyder T, McKean J, Wheatley M, Bhargava R, et al. Pediatric temporal lobectomy for epilepsy. Pediatr Neurosurg. 2003; 38: 195-205.
42. Sakuta R, Otsubo H, Nolan MA, Weiss SK, Hawkins C, Rutka JT, et al. Recurrent intractable seizures in children with cortical dysplasia adjacent to dysembrioplastic neuroepithelial tumor. Pediatr Neurol. 2005; 20: 377-384.
43. Steinbok P, Connolly M. Editorial comment. Child's Nerv Syst. 2000; 16: 286.
44. Thiele EA. Managing epilepsy in tuberous sclerosis complex. J Child Neurol. 2004; 19: 680-686.
45. Weiner HL, Ferraris N, LaJoie J, Miles D, Devinsky O. Epilepsy surgery for children with tuberous sclerosis complex. J Child Neurol. 2004; 19: 687-689.
46. Romanelli P, Verdecchia M, Rodas R, Seri S, Curatolo P. Epilepsy surgery for tuberous sclerosis. Pediatr Neurol. 2004; 31: 239-247.
47. Kossoff EH, Buck C, Freeman JM. Outcomes of 32 hemispherectomies for Sturge-Weber syndrome worlwide. Neurology. 2002; 59: 1.735-1.738.
48. Sasaki M, Hashimoto T, Furushima W, Okada M, Kinoshita S, Fujikawa Y, et al. Clinical aspects of hemimegalencephaly by means of a nationwide survey. J Child Neurol. 2005; 20: 337-341.
49. Freeman JM. Rasmussen's syndrome: progressive autoinmune multi-focal encephalopathy. Pediatr Neurol. 2004; 32: 295-299.
50. MacCracken KA, Scalisi JC. Development and evaluation of a ketogenic diet program. J Am Diet Assoc. 1999; 99: 1.554-1.558.
51. Kossoff EH. More fat and fewer seizures: dietary therapies for epilepsy. Lancet Neurol. 2004; 3: 415-420.
52. Maydell BV, Wyllie E, Akhtar N, Kotagal P, Powaski K, Cook K, et al. Efficacy of the ketogenic diet in focal versus generalized seizures. Pediatr Neurol. 2001; 25: 208-212.
53. Panico RL, Demartini MG, Ríos VG, Carniello MA. Dieta cetogénica en la epilepsia refractaria infantil: respuesta electroclínica, complicaciones y efectos secundarios. Rev Neurol. 2000; 31: 212-220.
54. Coppola G, Veggioti P, Cusmai R, Bertoli S, Cardinali S, Dionisi-Vici C, et al. The ketogenic diet in children, adolescents and young adults with refractory epilepsy: an Italian multicentric experience. Epilepsy Res. 2002; 48: 221-227.
55. DiMario FJ, Holland J. The ketogenic diet: a review of the experience at Connecticut Children's Medical Center. Pediatr Neurol. 2002; 26: 288-292.
56. François LL, Manel V, Rousselle C, David M. Le régime cétogène à visée anti-épileptique: son utilisation chez 29 enfants épileptiques. Arch Pediatr. 2003; 10: 300-306.
57. Kang HC, Kim YJ, Kim DW, Kim HD. Efficacy and safety of the ketogenic diet for intractable childhood epilepsy: Korean multicentric experience. Epilepsia. 2005; 46: 272-279.
58. Mady MA, Kossoff EH, McGregor AL, Wheless JW, Pycik PL, Freeman JM. The ketogenic diet: adolescentes can do it, too. Epilepsia. 2003; 44: 847-851.
59. Pulsifer MB, Gordon JM, Brandt J, Vining EP, Freeman JM. Effects of ketogenic diet on development and behavior: preliminary report of a prospective study. Dev Med Child Neurol. 2001; 43: 301-306.
60. Galván Manso M, Arellano M, Sans A, Sanmartí FX, Gómez L, Vernet A. Dieta cetogénica: ¿una alternativa válida en epilepsias refractarias? Rev Neurol. 2001; 33: 1.010-1.014.
61. Kang HC, Chung DE, Kim DW, Kim HD. Early- and late-onset complications of the ketogenic diet for intractable epilepsy. Epilepsy. 2004; 45: 1.116-1.123.
62. Stewart WA, Gordon K, Camfield P. Acute pancreatitis causing death in a child on the ketogenic diet. J Child Neurol. 2001; 16: 682.
63. Wheless JW. The ketogenic diet: an effective medical therapy with side effects. J Child Neurol. 2001; 16: 633-635.
64. Rubenstein JE, Kossoff EH, Pyzic PL, Vining EPG, McGrogan JR, Freeman JM. Experience in the use of the ketogenic diet as early therapy. J Child Neurol. 2005; 20: 31-34.
65. Levy R, Cooper P. Dieta cetogénica para la epilepsia (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, Número 2. Oxford: Update Software Ltd., 2005. Disponible en: http://www.update-software.com (traducida de The Cochrane Library, issue 2. Chichester: John Wiley & Sons, Ltd., 2005).
66. Kossoff EH, McGrogan JR. Worldwide use of the ketogenic diet. Epilepsia. 2005; 46: 280-289.
67. Forcadas-Berdusán MI. Indicaciones y resultados de los tratamientos no farmacológicos de las epilepsias: estimulación vagal, dieta cetógena y rayos gamma. Rev Neurol. 2002; 35 Supl 1: 144-150.
68. Gupta R, Appleton R. Corticosteroids in the management of the paediatric epilepsies. Arch Dis Child. 2005; 90: 379-384.
69. Okuyaz Ç, Aydin K, Gücüyener K, Serdaroglu A. Treatment of electrical status epilepticus during slow-wave sleep with high-dose corticosteroid. Pediatr Neurol. 2005; 32: 64-67.
70. Sinclair DB, Snyder TJ. Corticosteroids for the treatment of Landau-Kleffner syndrome and continuous spike-wave discharge during sleep. Pediatr Neurol. 2005; 32: 300-306.
71. O'Regan ME, Brown JK. Is ACTH a key to understanding anticonvulsant action? Dev Med Child Neurol. 1998; 40: 82-89.
72. Gobbi G, Raimondi R, Boni A, Bertani G, Della Giustina E. The pharmacological approach in frontal lobe epilepsies. Rev Neurol. 2005; 40: 11.
73. Espinosa-Zacarías JP, Gutiérrez-Moctezuma J, Villegas-Peña H, Olmos G, De Alba G. Tratamiento intravenoso con inmunoglobulinas en síndromes epilépticos de difícil control. Rev Neurol. 2002; 34: 816-819.
74. Carrillo Herranz A, Sánchez Perez I, Aparicio-Meix JM, Lozano Giménez C, Roy Ariño G, Villar Gimerans LM, et al. Síndrome de Rasmussen: una enfermedad autoinmune. An Pediatr (Bare). 2003; 59: 187-189.
75. Villani F, Avanzini G. The use of immunoglobulins in the treatment of human epilepsy. Neurol Sci. 2002; 23: 3S-37S.
76. Iriarte J, Urrestarazu E, Lázaro D, Schlumberger E. Estimulación vagal en el tratamiento de la epilepsia. Rev Neurol. 2002; 34: 511-518.
77. Murphy JV; Pediatric VNS Study Group. Left vagal nerve stimulation in children with medically refractory epilepsy. J Pediatr. 1999; 134: 563-566.
78. Helmers SL, Wheless JW, Frost M, Gates J, Levisohn P, Tardo C, et al. Vagus nerve stimulation therapy in pediatric patients with refractory epilepsy: retrospective study. J Child Neurol. 2001; 16: 843-848.
79. Zamponi N, Rychlicki F, Cardinali C, Luchetti A, Trignani R, Ducati A. Intermittent vagal nerve stimulation in paediatric patients: 1-year follow-up. Childs Nerv Syst. 2002; 18: 61-66.
80. Murphy JV, Torkelson R, Dowler I, Simon S, Hudson S. Vagal nerve stimulation in refractory epilepsy: the first 100 patients receiving vagal nerve stimulation at a pediatric epilepsy center. Arch Pediatr Adolesc Med. 2003; 157: 560-564.
81. Parker AP, Polkey CE, Binnie CD, Madigan C, Ferrie CD, Robinson RO. Vagal nerve stimulation in epileptic encephalopathies. Pediatrics. 1999; 103: 778-782.
82. Aicardi J. Vagal nerve stimulation in epileptic encephalopathies. Pediatrics. 1999; 103: 821-822.
83. Hosain S, Nikalov B, Harden C, Li M, Fraser R, Labar D. Vagus nerve stimulation treatment for Lennox-Gastaut syndrome. J Child Neurol. 200; 15: 509-512.
84. Parain D, Penniello MJ, Berquen P, Delangre T, Billard C, Murphy JV. Vagal nerve stimulation in tuberous sclerosis complex patients. Pediatr Neurol. 2001; 25: 213-216.
85. Murphy JV, Wheless JW, Schmoll CM. Left vagal nerve stimulation in six patients with hypothalamic hamartomas. Pediatr Neurol. 2000; 23: 167-168.
86. Chawla J, Sucholeiki R, Jones C, Silver K. Intractable epilepsy with ring chromosome 20 syndrome treated with vagal nerve stimulation: case report and review of the literature. J Child Neurol. 2002; 17: 778-780.
87. Sánchez-Álvarez JC; Grupo Andaluz Interdisciplinario contra la Epilepsia. Unidades clínicas de epilepsia. Rev Neurol. 2003; 37: 790-796.